Q32 Bio Inc. (QTTB)
NASDAQ: QTTB · Real-Time Price · USD
1.715
+0.045 (2.69%)
Sep 8, 2025, 1:08 PM - Market open
Q32 Bio Employees
As of December 31, 2024, Q32 Bio had 43 total employees, including 42 full-time and 1 part-time employees. The number of employees increased by 6 or 16.22% compared to the previous year.
Employees
43
Change (1Y)
6
Growth (1Y)
16.22%
Revenue / Employee
n/a
Profits / Employee
-$1,216,372
Market Cap
20.92M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 43 | 6 | 16.22% |
| Dec 31, 2023 | 37 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
QTTB News
- 11 days ago - Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference - PRNewsWire
- 4 weeks ago - Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer - PRNewsWire
- 4 months ago - Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 4 months ago - Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata - PRNewsWire
- 5 months ago - Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata - PRNewsWire
- 6 months ago - Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 6 months ago - Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting - PRNewsWire